Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 21Colorectal Neoplasms 8Colonic Neoplasms 6Carcinoma, Hepatocellular 6Rectal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Pancreatic Neoplasms 3Biliary Tract Neoplasms 3Head and Neck Neoplasms 2HER2-positive Gastric Cancer 2Gallbladder Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Recurrence 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Lung Neoplasms 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1Efficacy and Safety 1Drug-Related Side Effects and Adverse Reactions 1Cholangiocarcinoma 1

Interventions

tislelizumab 2disitamab vedotin 2Trastuzumab 2Tegafur 2S 1 (combination) 1Oxaliplatin 1HMPL-013 1Drug Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × HER2-positive Gastric Cancer × Tegafur × Clear all
NCT06439550 2024-06-03

Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC

The First Affiliated Hospital of Zhengzhou University

Phase 2 Not yet recruiting
42 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

NCT05070598 2021-10-07

Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer

Shengjing Hospital

Phase 2 Unknown
35 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡